Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 2,300 shares, a decrease of 88.7% from the November 30th total of 20,400 shares. Based on an average daily volume of 198,200 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Price Performance

OTCMKTS:CHGCY traded down $0.06 during trading hours on Thursday, reaching $21.95. 78,931 shares of the company were exchanged, compared to its average volume of 127,127. The firm has a market cap of $72.24 billion, a price-to-earnings ratio of 28.14 and a beta of 0.82. The stock has a 50 day simple moving average of $22.50 and a 200 day simple moving average of $21.74. Chugai Pharmaceutical has a 52-week low of $14.52 and a 52-week high of $26.00.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.